Profusa, Inc. Common Stock Total Liabilities
Profusa, Inc. Common Stock total liabilities. Based on the latest financial reports, Profusa, Inc. Common Stock (PFSA) has total liabilities worth $29.06 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PFSA financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Profusa, Inc. Common Stock (2021–2025)
Total liabilities of Profusa, Inc. Common Stock from 2021 to 2025. This chart illustrates how Profusa, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Profusa, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Profusa, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GeoVax Labs Inc
NASDAQ:GOVX
|
USA | $1.82 Million |
|
Medivie Therapeutic Ltd
TA:MDVI
|
Israel | ILA9.13 Million |
|
LIVE MOTION GAMES ZY -10
F:4YM
|
Germany | €3.45 Million |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
UK | GBX3.65 Million |
|
Yuilrobotics Co. Ltd.
KQ:388720
|
Korea | ₩18.52 Billion |
|
Carclo plc
LSE:CAR
|
UK | GBX101.03 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Profusa, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Profusa, Inc. Common Stock.
Liquidity & Leverage Metrics
Profusa, Inc. Common Stock Total Liabilities Ratios Explained
Profusa, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 33.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Profusa, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Profusa, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of Profusa, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $30.43 Million | -75.11% |
| 2024-12-31 | $122.28 Million | +9.29% |
| 2023-12-31 | $111.89 Million | +11.00% |
| 2022-12-31 | $100.80 Million | +6.09% |
| 2021-12-31 | $95.02 Million | -- |
About Profusa, Inc. Common Stock
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platf… Read more